235 related articles for article (PubMed ID: 28126150)
1. Drug-Induced QTc Prolongation.
Riad FS; Davis AM; Moranville MP; Beshai JF
Am J Cardiol; 2017 Jan; 119(2):280-283. PubMed ID: 28126150
[TBL] [Abstract][Full Text] [Related]
2. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
3. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
[TBL] [Abstract][Full Text] [Related]
4. Drug-Induced QTc Prolongation: What We Know and Where We Are Going.
Mangona E; Sandonato E; Brothers TN; Pawasauskas J
Curr Drug Saf; 2022; 17(2):100-113. PubMed ID: 34551700
[TBL] [Abstract][Full Text] [Related]
5. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation.
Patel N; Veve M; Kwon S; McNutt LA; Fish D; Miller CD
HIV Med; 2013 Sep; 14(8):463-71. PubMed ID: 23506263
[TBL] [Abstract][Full Text] [Related]
6. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and determinants of QT interval prolongation in medical inpatients.
Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
[TBL] [Abstract][Full Text] [Related]
8. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
[TBL] [Abstract][Full Text] [Related]
10. Incidence and outcomes of long QTc in acute medical admissions.
Mahmud R; Gray A; Nabeebaccus A; Whyte MB
Int J Clin Pract; 2018 Nov; 72(11):e13250. PubMed ID: 30222237
[TBL] [Abstract][Full Text] [Related]
11. Prolongation of the QTc interval in HIV-infected individuals compared to the general population.
Reinsch N; Arendt M; Geisel MH; Schulze C; Holzendorf V; Warnke A; Neumann T; Brockmeyer NH; Schadendorf D; Eisele L; Erbel R; Moebus S; Jöckel KH; Esser S;
Infection; 2017 Oct; 45(5):659-667. PubMed ID: 28776165
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Cirrhosis and Prescription Medications on QTc Interval Before and After Liver Transplantation.
Santeusanio AD; Dunsky KG; Pan S; Schiano TD
J Pharm Pract; 2019 Feb; 32(1):48-53. PubMed ID: 29092657
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
Jardin CG; Putney D; Michaud S
Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
[TBL] [Abstract][Full Text] [Related]
14. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009.
Xiang YT; Chiu HF; Ungvari GS; Correll CU; Lai KY; Wang CY; Si TM; Lee EH; He YL; Yang SY; Chong MY; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Tan CH; Shinfuku N
Hum Psychopharmacol; 2015 Mar; 30(2):94-9. PubMed ID: 25611192
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors of QTc Prolongation in Women With Hormone Receptor‒positive/Human Epidermal Growth Factor Receptor 2‒negative Metastatic Breast Cancer: A Retrospective Analysis of Health Care Claims Data.
Ward M; Harnett J; Bell TJ; Mardekian J
Clin Ther; 2019 Mar; 41(3):494-504.e1. PubMed ID: 30792074
[TBL] [Abstract][Full Text] [Related]
16. Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations
.
Keller GA; Villa Etchegoyen MC; Fernández N; Olivera NM; Quiroga PN; Diez RA; Di Girolamo G
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):275-285. PubMed ID: 27509828
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and factors associated with QTc prolongation among emergency department patients.
Seftchick MW; Adler PH; Hsieh M; Wolfson AB; Chan ST; Webster BW; Frattaroli GD
Ann Emerg Med; 2009 Dec; 54(6):763-8. PubMed ID: 19419793
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of QTc Prolongation in Patients With Advanced Cancer Receiving Palliative Care-A Cause for Concern?
Hardy JR; Bundock D; Cross J; Gibbons K; Pinkerton R; Kindl K; Good P; Philip J
J Pain Symptom Manage; 2020 Apr; 59(4):856-863. PubMed ID: 31866486
[TBL] [Abstract][Full Text] [Related]
19. QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.
Berger FA; Monadian N; de Groot NMS; Santbergen B; van der Sijs H; Becker ML; Broers AEC; van Gelder T; van den Bemt PMLA
Br J Clin Pharmacol; 2018 Feb; 84(2):369-378. PubMed ID: 29057492
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors.
Ng TM; Olsen KM; McCartan MA; Puumala SE; Speidel KM; Miller MA; Sears TD
J Pharm Pract; 2010 Feb; 23(1):19-24. PubMed ID: 21507789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
